| Huang et al. 2010 [56] | Huang et al. 2013 [57] |
---|---|---|
Study design | RCT | RCT |
Study population (n) | 44 sepsis or septic shock patients | 46 ALI/extra-pulmonary sepsis patients |
EAA assessment | – | – |
Prescribed dose | HP for 2Â h for 3Â days | HP for 2Â h for 3Â days |
Survival | • ICU mortality 12.5% in HA vs 45.0% in the controls (p = 0.02) • Hospital mortality 37.5% in HA vs 50.0% in the controls (p = 0.81) • 28-day mortality 45.8% in HA vs 55.0% in controls (p = 0.47) | • ICU mortality 24% in HA vs 57.14% in the controls (p = 0.02) • 28-day mortality 28% in HA vs 66.7% in the controls (p = 0.009) |
Length of ICU stay (days) | 12.4 ± 3.1 in HA vs 19.5 ± 4.0 in controls (p = 0.03) | 15.5 ± 4.0 in HA vs 19.4 ±  3.1 in controls (p = 0.04) |
Hemodynamics | Significant reduction in VP dose in the HA group vs increase in the control group (p = 0.01) | Significant reduction in VP dose in the HA group vs increase in the control group (p = 0.032) |
Other results | Significant difference in IL-8 and IL-6 levels between the two groups at day 3 (p = 0.03 and 0.01, respectively) | Significant difference in IL-1 and TNF-a in BAL fluid between the two groups (p = 0.02 and 0.04, respectively) |
Safety | • 1 patient with fever in the HA group • Transient reduction in platelet counts in the HP group | – |